Market revenue in 2023 | USD 75.7 million |
Market revenue in 2030 | USD 126.1 million |
Growth rate | 7.6% (CAGR from 2023 to 2030) |
Largest segment | Hereditary non-cancer testing |
Fastest growing segment | Hereditary Cancer Testing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hereditary Cancer Testing, Hereditary Non-cancer Testing |
Key market players worldwide | Myriad Genetics Inc, Invitae Corp, Illumina Inc, Natera Inc, Labcorp Holdings Inc, Roche Holding AG ADR, Quest Diagnostics Inc, CooperSurgical, Agilent Technologies Inc, Thermo Fisher Scientific Inc, Twist Bioscience Corp, Sophia Genetics SA, Fulgent Genetics Inc, MedGenome, Centogene NV Ordinary Shares, The Cooper Companies Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary testing market will help companies and investors design strategic landscapes.
Hereditary non-cancer testing was the largest segment with a revenue share of 88.24% in 2023. Horizon Databook has segmented the South Africa hereditary testing market based on hereditary cancer testing, hereditary non-cancer testing covering the revenue growth of each sub-segment from 2018 to 2030.
Ongoing research studies by several researchers to evaluate incidence of hereditary cancers and consequently raise awareness about them among South African population is expected to drive market growth over the forecast period.
A research study by F. Z. Francies et al., published in November 2015, determined frequency and spectrum of gene mutations in BRCA1, BRCA2, and PALB2 to estimate risk of breast cancer. The study highlighted importance of evaluating germline mutations in several South African population groups.
A study by Emmanuel Amankwaa-Frempong et al., published in August 2017, stated that Triple-negative Breast Cancer (TNBC) is a risk factor for inherited breast cancer in South Africa. These studies expand the knowledge & awareness about hereditary breast cancer among the African population and healthcare providers, creating lucrative opportunities for market participants to provide hereditary testing solutions in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the South Africa hereditary testing market, including forecasts for subscribers. This country databook contains high-level insights into South Africa hereditary testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account